Guidance

Candida auris: laboratory investigation, management and infection prevention and control

Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris (C. auris).

• From: Public Health England
• Published: 27 June 2016
• Last updated: 11 August 2017 — See all updates

Documents

Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris

Ref: PHE publications gateway number: 2016122

PDF, 360 KB, 16 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This guidance is under review. An updated version is currently under consultation. This page will be updated with the new guidance once the process has concluded.

Candida auris is a pathogenic yeast species that has been reported to cause bloodstream infections, wound infections, and otitis. It has also been cultured from urine and the respiratory tract. Unlike other pathogenic yeast species, C. auris appears to have a propensity for transmission between hospital patients. It is commonly resistant to the first-line antifungal, fluconazole and can develop resistance to other classes of anti-fungal agents.

This document provides guidance about sending Candida spp isolates for laboratory testing, treatment and decolonisation of patients and screening in hospitals, and infection prevention and control measures.

Published 27 June 2016
Last updated 11 August 2017 + show all updates

1. 11 August 2017

   Updated version of guidance for laboratories, healthcare providers and healthcare professionals replaces that first published in 2016.

2. 27 June 2016

   First published.